By encoding instructions that can be selectively read by the cells we target, our designer mRNA promotes healing ( I ) and suppresses disease ( O ) like an on-off switch with unprecedented precision.
Our patented engineering methods are complemented by a clinically validated delivery system that drives our therapeutic mRNA to the target tissue.
Legacy approaches to mRNA design are poor at targeting specific cells within tissue and tumor microenvironments. Fuzzy cell selection is a key barrier to therapeutic relevance.
Hyperselective activation is the kernel of mRNA 2.0.See how it works